Opinion|Videos|March 29, 2025
Utilizing Intravenous and Subcutaneous Formulations of Spesolimab
Panelists compare the results of the EFFISAYIL-1 and -2 trials with real-world use of spesolimab; discuss treatment expectations with patients; and explore the similarities, differences, and management roles of intravenous (IV) and subcutaneous (SQ) formulations, with strategies for timely IV therapy initiation during flares.
Advertisement
Video content above is prompted by the following:
Episodes in this series
- How do the results of EFFISAYIL-1 and -2 compare with the results you have seen with spesolimab in clinical practice?
a. How do you discuss treatment expectations for spesolimab with your patients? - Discuss the utility of both an IV and SQ formulation of spesolimab. How are they similar and different, and how are both formulations used in the management of GPP?
a. PK modeling (Hawkes, 2024)
b. How do you ensure timely initiation of IV therapy and continuity of care when a patient is experiencing a flare?
Advertisement
Related to this article
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.
In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.
In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.
Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.
A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.
Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
In a LIBERTY post hoc analysis, most patients restarting infliximab as SC 240 mg after a drug holiday had prior ADAs, yet outcomes were similar.
Advertisement
Advertisement
Trending on HCPLive
1
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
2
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
3
Rezpegaldesleukin Hair Regrowth Climbs Through 1 Year in AA: David Rosmarin, MD
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5